MVA-CSO

MVA-CSO is a recombinant viral vector vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) for the prevention of malaria caused by *Plasmodium falciparum*. It utilizes the Modified Vaccinia Ankara (MVA) virus as a delivery vector to express a codon-optimized version of the circumsporozoite protein (CSP), which is the dominant surface antigen of the malaria sporozoite. In clinical development, MVA-CSO is primarily evaluated as a booster component in heterologous prime-boost immunization regimens, typically following a DNA vaccine prime (such as PfCSP DNA/VCL-2510). This strategy is designed to elicit robust cellular and humoral immune responses against the pre-erythrocytic stage of the parasite, aiming to prevent the infection of hepatocytes and the subsequent progression to symptomatic blood-stage malaria.

Other names

Modified Vaccinia Ankara-Circumsporozoite ProteinMVA-PfCSP